3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Advanced Solid Tumor
12
Solid Tumor
6
Advanced Solid Tumors
5
Sarcoma
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumors
2
Small Cell Lung Carcinoma
2
Mesothelioma
2
Melanoma
2
Carcinoma, Renal Cell
2
Anus Neoplasms
2
Advanced Solid Tumour
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Germ Cell Tumor
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Neoplasms, Unknown Primary
1
Metastatic Solid Tumors
1
Mesothelioma, Malignant
1
Malignant Solid Tumors
1
MSI-H/dMMR Solid Tumors
1
MSI-H Colorectal Cancer
1
Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in
1
Locally Advanced or Metastatic Solid Tumors
1
Locally Advanced and Metastatic Solid Tumors
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Interventions
pembrolizumab
7
Radiotherapy
3
Proton Therapy
3
Interleukin-2
3
Cyclophosphamide
3
spartalizumab
2
fludarabine
2
Rosuvastatin Calcium
2
Paclitaxel
2
Ipilimumab
2
Immune Checkpoint Inhibitors
2
Cetuximab
2
Carboplatin
2
Blood Specimen Collection
2
toripalimab
1
tislelizumab
1
sotorasib
1
peposertib
1
pazopanib
1
patritumab deruxtecan
1
palbociclib
1
osimertinib
1
niraparib
1
neotil
1
necitumumab
1
mirdametinib
1
leronlimab
1
lenvatinib
1
atezolizumab
1
apatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Solid Tumor, Adult
×
tislelizumab
×
Other solid neoplasm
×
Clear all
NCT06032845
2025-02-27
CASTLE-11
Fudan University
Phase 2
Recruiting
25 enrolled